Scott Dreyer - 18 Aug 2025 Form 4 Insider Report for COLLEGIUM PHARMACEUTICAL, INC (COLL)

Role
EVP & Chief Commercial Officer
Signature
/s/ Colleen Tupper as Attorney-In-Fact For Scott Dreyer
Issuer symbol
COLL
Transactions as of
18 Aug 2025
Transactions value $
-$276,430
Form type
4
Filing time
20 Aug 2025, 16:57:07 UTC
Previous filing
15 Aug 2025
Next filing
10 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dreyer Scott EVP & Chief Commercial Officer C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON /s/ Colleen Tupper as Attorney-In-Fact For Scott Dreyer 20 Aug 2025 0001746251

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction COLL Common Stock Options Exercise $350K +16.4K +15.82% $21.34 120K 18 Aug 2025 Direct F1
transaction COLL Common Stock Sale -$626K -16.4K -13.66% $38.21 104K 18 Aug 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COLL Stock Option (Right to Purchase) Options Exercise $0 -16.4K -100% $0.00 0 18 Aug 2025 Common Stock 16.4K $21.34 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024.
F2 The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.00 to $38.465, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The option is fully vested and exercisable.

Remarks:

Exhibit 24.1 - Power of Attorney